Anthony Kong

11PUBLICATIONS
20CO-AUTHORS
Molecular targetsPredictive and prognostic markersRegenerative medicine (incl. stem cells)Radiation therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Nov 25, 2024
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer.

Abul Azad, Maryam Arshad, Daniele Generali

|Oct 10, 2024
Correlation of the treatment sensitivity of patient-derived organoids with treatment outcomes in patients with head and neck cancer (SOTO): protocol for a prospective observational study.

Ifigenia Vasiliadou, Christiana Cattaneo, Phoebe Yuen Ka Chan

|Jul 06, 2024
Fusobacterium is toxic for head and neck squamous cell carcinoma and its presence may determine a better prognosis.

Anjali Chander, Jacopo Iacovacci, Aize Pellon

|Apr 30, 2024
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK.

Ifigenia Vasiliadou, Derek Grose, Christina Wilson

|Apr 10, 2024
Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.

Maryam Arshad, Abul Azad, Phoebe Yuen Ka Chan

|Jan 26, 2023
The Impact of Interactive MRI-Based Radiologist Review on Radiotherapy Target Volume Delineation in Head and Neck Cancer.

D Adjogatse, I Petkar, M Reis Ferreira

Pageof 2

Frequent Collaborators

2 joint publications

Miguel Reis Ferreira

2 joint publications

Ifigenia Vasiliadou

1 joint publications

D Adjogatse

1 joint publications

M Lei